Autopsy report · NCT05653661

Nab-Paclitaxel/STI-3031 Complex (AP160-Complex) for the Treatment of Advanced or Metastatic Solid Tumors

“Sponsor business considerations”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Phase 1

Sponsor

Mayo Clinic

Sponsor type

University, hospital or other

Conditions

Advanced Malignant Solid Neoplasm; Metastatic Malignant Solid Neoplasm; Unresectable Melanoma

Interventions

Biopsy; Biospecimen Collection; Computed Tomography; Magnetic Resonance Imaging; Nab-paclitaxel/Danburstotug Complex AP160

Participants

0

Sites

1

Countries

United States

Trials that died the same way

• Novum Vitrium® Cervical Cage in Anterior Cervical Discectomy and Fusion
  “Sponsor business decision” (90% match in meaning)
• Study of Vitespen (HSPPC-96, Oncophage ®) for Immune Response Assessment in Participants With Resectable Renal Cell Carcinoma at Intermediate Risk of Recurrence
  “Sponsor's business decision” (88% match in meaning)
• Evaluation of Efficacy and Safety of Hyaluronic Acid (HA) Product for Cheek Augmentation
  “Sponsor business reasons” (88% match in meaning)
• Study With Bispecific Antibody Engaging T-cells, in Patients With Progressive Cancer Diseases With Positive PSCA Marker
  “business decision by sponsor” (84% match in meaning)
• Study of Efficacy, Safety, and Tolerability of LYS006, in Patients With Mild to Moderate Ulcerative Colitis
  “Sponsor decision due to strategic considerations” (82% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.